Abstract: Provided are a method for inactivating respiratory syncytial virus (RSV) and stabilizing pre-F protein in RSV and inactivated RSV virus obtained thereby. Also provided are a vaccine comprising the inactivated RSV virus and a use of the vaccine in preventing or treating RSV infection or a disease related thereto.

Abstract: Provided herein is a pharmaceutical formulation comprising a protein based excipient in combination with an active pharmaceutical ingredient (API) wherein said formulation is substantially amorphous and form a substantially homogenous mixture; and further a method for producing said pharmaceutical formulation; and said pharmaceutical formulation for use as a medicament.

Abstract: The present invention relates to hyper harmonized hydroxyl-modified fullerenes, hydroxyl-modified fullerenes in a suitable carrier, and hydroxyl-modified fullerene formulations including a suitable carrier with optional additives. These compositions of matter and formulations have numerous applications including, for example, the cosmetic industry, dietary supplements, food industry, plants and healthcare fields.

Abstract: The present application relates to an aqueous pharmaceutical composition for use as a paediatric medicament in the treatment or prevention of vitamin A deficiency or a vitamin A deficiency-associated disease.

Abstract: The present invention relates to a capsule shell with two parts, a cap and a body, the two parts engage telescopically with each other, the capsule shell is used for storing solid substances in powder or granular form and shows a minimized leakage rate of powder when the capsule shell is filled with the solid substances in powder form and is closed.

Abstract: Shear-thinning biomaterial technology offers enables polymers and drugs loaded inside such polymers to be easily delivered directly through catheters into target area for use, for example, in cancer therapy and immunotherapy. When a force above a certain threshold is applied to inject such materials, they “thin” and behaves as a semi-solid, allowing the material to readily flow through a catheter. When the force is removed, the material instantly becomes a soft solid with significant cohesive properties that prevent it from dislodging or breaking up. We have developed novel shear-thinning biomaterials using spherical silica nanoparticles and gelatin-based polymers. Rheological tests confirm that these materials have excellent shear-thinning properties and further have improved material properties (e.g. improved stability profiles) as compared conventional materials available to medical professionals.

Abstract: A method for skin protection by applying a zinc oxide-on-silicate platelet composite (ZnO/NSP composite) is formulated in a cosmetic composition, to the skin of a subject. The ZnO/NSP composite is made of silicate platelet and ZnO particles adsorbed thereon, in which the ZnO particles are created by the dehydration of Zn(OH)2 formed on the silicate platelet. The ZnO particles adhering on the silicate platelet can effectively improve the dispersibility of zinc oxide particles in water, and the average particle size can reach near nanometer size. Moreover, the ZnO/NSP composite exhibits better antimicrobial and UV light-absorbing properties than ZnO itself, and are not toxic or irritating to the skin.

Abstract: Cyclic pentapeptides are disclosed having the following formula (I)-Cyclo(-A1-A2-A3-A4-A5-)-wherein A1, A2, A3, A4 and A5 are amino acid residues. The pentapeptide has amino acid residues in positions 1-2-3 to form a &ggr;-turn, and amino acid residues in positions 3-4-5-1 to form a &bgr;-turn in combination with the &ggr;-turn. D-&agr;-amino acid residues are selected for A1, A3, and A5 and L-&agr;-amino acid residues are selected for A2 and A4. Compounds having &ggr;-turns and &bgr;-turns can be synthesized, regardless of the kinds of amino acid residues, and it is possible to synthesize compounds in which desired amino acid residues are introduced into sites of &bgr;-turn and &ggr;-turn based on their importance from the viewpoint of biological activity. The present invention is therefore available for design of compounds having biological activity.